--- title: Sciensus Appoints James Tugendhat OBE as Chief Executive Officer description: Sciensus appoints James Tugendhat OBE, former Group CEO of HC-One, as Chief Executive Officer, succeeding interim CEO Gordon Cox, who stays on as COO. image: https://news.lifesciencenewswire.com/hubfs/Sciensus%20Appoints%20James%20Tugendhat%20OBE%20as%20%20Chief%20Executive%20Officer.png --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [AI (2)](https://news.lifesciencenewswire.com/newsroom/tag/ai) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (37)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (23)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (17)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (254)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (10)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (38)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (118)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (289)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (38)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Digital Pathology (2)](https://news.lifesciencenewswire.com/newsroom/tag/digital-pathology) - [Drug Discovery & Development (154)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (58)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (137)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (7)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (27)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (88)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (118)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (5)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (6)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [Sciensus Appoints James Tugendhat OBE as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/sciensus-appoints-james-tugendhat-obe-as-chief-executive-officer) October 28, 2026 [![Sciensus Appoints James Tugendhat OBE as Chief Executive Officer](https://news.lifesciencenewswire.com/hs-fs/hubfs/Sciensus%20Appoints%20James%20Tugendhat%20OBE%20as%20%20Chief%20Executive%20Officer.png?width=433&height=284&name=Sciensus%20Appoints%20James%20Tugendhat%20OBE%20as%20%20Chief%20Executive%20Officer.png)](https://drive.google.com/file/d/1O9do9vdgd2FbxOvYcMe4jwRejbSfohyw/view?usp=drive_link)[Sciensus](https://www.sciensus.com/) has appointed James Tugendhat OBE as Chief Executive Officer, bringing more than 20 years of leadership experience across healthcare and complex service organisations.  James was most recently Group CEO of HC-One, the UK's largest care home operator. His previous leadership roles include senior positions at Bupa, including as CEO of Health Dialog, a pioneering US health analytics and chronic disease management company. He also served, for seven years, as a non-executive director of the Royal Free London NHS Foundation Trust. He takes over for Gordon Cox, who led the business as interim CEO during the Board’s search for a new CEO, and who continues as Chief Operating Officer and as a member of key company boards.  Peter Nicklin, Chairman, Sciensus, said: “We’re delighted to welcome James to Sciensus. He understands what it takes to run a regulated, people-centred healthcare business, and he brings extensive experience of the wider healthcare sector. On behalf of the Board, I also want to thank Gordon for his leadership and contributions over the last few months.” James Tugendhat, CEO, Sciensus, said: “Sciensus plays a vital role in helping patients access specialist medicines and care, including treatments that can be delivered in their own homes. I'm looking forward to working with colleagues across the business, understanding their experiences and building on the deep expertise already in place to support patients, healthcare providers and our biotech and pharmaceutical partners.”   **About Sciensus** Sciensus connects the people, infrastructure, care and evidence that help specialist medicines deliver their full value. For more than 30 years, Sciensus has worked with the NHS to provide specialist clinical nursing and patient support in patients’ homes across cancer, rare disease and chronic conditions, caring for more than 300,000 patients each year across 180+ NHS trusts in the UK. Across Europe, Sciensus provides commercialisation expertise and operational infrastructure to help global pharmaceutical and biotech companies bring medicines to patients in multiple markets. Through the care it delivers, Sciensus also generates real-world evidence that helps demonstrate the value of treatments and improve future care. Categories: [Pharma](https://news.lifesciencenewswire.com/newsroom/tag/pharma), [Corporate, Finance & Investor](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor), [biopharma](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) ##### Browse more news ## Recent releases #### [Sciensus Appoints James Tugendhat OBE as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/sciensus-appoints-james-tugendhat-obe-as-chief-executive-officer) October 28, 2026 Sciensus has appointed James Tugendhat OBE as Chief Executive Officer, bringing more than 20 years of leadership experience across healthcare and comp... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/sciensus-appoints-james-tugendhat-obe-as-chief-executive-officer) #### [Takara Bio Europe Introduces GMP-Grade Cellartis® MSC EV Wonder™ to Support Clinical-Scale Extracell...](https://news.lifesciencenewswire.com/newsroom/takara-bio-europe-introduces-gmp-grade-cellartis-msc-ev-wonder-to-support-clinical-scale-extracellular-vesicle-production) October 28, 2026 Takara Bio Europe announces the introduction of a Good Manufacturing Practice (GMP)-grade version of Cellartis® MSC EV Wonder™, its defined, xeno-free... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/takara-bio-europe-introduces-gmp-grade-cellartis-msc-ev-wonder-to-support-clinical-scale-extracellular-vesicle-production) #### [Samplix Secures Backing to Accelerate Xdrop’s Commercial Expansion in Antibody Discovery](https://news.lifesciencenewswire.com/newsroom/samplix-secures-backing-to-accelerate-xdrops-commercial-expansion-in-antibody-discovery) October 27, 2026 WLan-led financing reaches a €25 million first closing, comprising €3 million in new capital and €22 million in shareholder convertible-bond conversio... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/samplix-secures-backing-to-accelerate-xdrops-commercial-expansion-in-antibody-discovery) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)